{"nctId":"NCT01726049","briefTitle":"Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH","startDateStruct":{"date":"2011-10"},"conditions":["Heart Failure, Diastolic","Pulmonary Hypertension"],"count":52,"armGroups":[{"label":"Sildenafil","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sildenafil"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sildenafil","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* \\>18 years\n* Written inform consent\n* PH secondary to diastolic left heart failure defined as\n* PAP mean \\>25 mmHg\n* Wedge mean \\>15 mmHg\n* Normal systolic left ventricular (LV) function on echo/nuclear imaging (left ventricular ejection fraction (LVEF) \\> or =45%)\n* New York Heart Association class (NYHA) II-IV despite heart failure therapy\n\nExclusion Criteria:\n\n* Severe noncardiac limitation to exercise (as severe chronic obstructive pulmonary disease)\n* Other cause of PH besides diastolic heart failure\n* Coronary ischemia or recent myocardial infarction (\\<6 months)\n* Hypotension ( \\<90/50 mmHg)\n* Ongoing nitrate therapy\n* Ongoing therapy with citochrome P450 3A4 ( CYP3A4) inhibitors (ketoconazole, erythromycin, cimetidine, clarithromycin, itraconazole, voriconazole and protease inhibitors) or CYP3A4 inductors(carbamacepine, phenytoin, phenobarbital, rifampicin, Sint Janskruid ). Furthermore patients will be informed not to drink grapefruit juice while on study medication because of the known impact of grape fruit on pharmacokinetics of Sildenafil.\n* Ongoing therapy with alpha -inhibitors\n* Significant mitral or aortic valve dysfunction\n* Severe liver dysfunction\n* Pregnancy\n* Unable to read and comprehend Dutch language","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization","description":"change of mean pulmonary artery pressure between baseline and 12 weeks measured by heart catheterisation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":null},{"groupId":"OG001","value":"-4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"VO2max","description":"difference in change of VO2 max between baseline and 12 weeks between Sildenafil and placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Cardiac Output Measured Invasively by Right Heart Catheterization","description":"difference in change of cardiac output between baseline and 12 weeks between Sildenafil and Placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Wedge Pressure Measured Invasively by Right Heart Catheterization","description":"Difference in change of wedge pressure between baseline and 12 weeks between Sildenafil group and Placebo group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-3.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Echocardiographic Parameters of Diastolic LV Dysfunction","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":26},"commonTop":["respiratory tract infection","myalgia","headache","visual impairment","nausea"]}}}